Genmab — Januar 2018
-
Har lige kigget lidt på Artisan og faldt lige over denne her. https://www.reuters.com/article/us-johnson-johnson-activist/investor-pressures-jj-to-consider-split-up-sources-idUSKCN0V601Y Vil undersøge mere, men det ligner en shareholder der presser ledelser af en vis kaliber, måske et split som minimum er på vej?
-
Kunne man sagtens forestille sig men det er jo ikke sjovt at sidde at skrive om, det er klart sjovere at grave informationer frem og sætte dem sammen i en brainstorm eller? Tænk nu hvis der faktisk er en konspiration, så er det rart at være på forkant.
-
Nu må Nordea godt snart begynde at tage lidt fra også
-
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, forecasts 25 to 30 percent royalty revenue growth in 2018 and potential for royalty revenue to reach nearly $1 billion in 2027 based on the current and expected momentum of partners coformulating products with its ENHANZE
technology. -
or we are betting on a Horse, there is not for sale. Even better in my eyes
-
Hopefully the thing we've got in pibeline is worth a lot more than a potential buyer would offer us within the next half year or so
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind